Form 4: Olema Pharmaceuticals Director Andrew Rappaport Granted Stock Options

Olema Pharmaceuticals Director Andrew Rappaport was granted 24,150 stock options with an exercise price of $4.08, vesting over 12 months or until the next annual meeting.

Summary

• Andrew Rappaport, a Director of Olema Pharmaceuticals, Inc. (OLMA), was granted stock options on June 11, 2025.
• He received 24,150 stock options to purchase common stock.
• The exercise price for these options is $4.08 per share.
• The options vest in 12 equal monthly installments starting June 11, 2025, contingent on his continuous service.
• Full vesting will occur by the date of the Issuer's next annual meeting of stockholders if not already fully vested, also subject to continuous service.
• The options expire on June 11, 2035.
• Following this transaction, Andrew Rappaport directly beneficially owns 24,150 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a routine grant of stock options to a director, which is a standard compensation practice and generally viewed as a positive for aligning management interests with shareholders, without indicating any unusual or negative events.

Positives

• The grant of 24,150 stock options to Director Andrew Rappaport aligns his interests with shareholder value creation.
• The options have a 10-year expiration date (June 11, 2035), providing a long-term incentive for the director.

Future Outlook

The vesting schedule for the stock options, which extends over 12 months or until the next annual meeting, indicates an expectation of Andrew Rappaport's continued service to Olema Pharmaceuticals.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and director compensation packages designed to align leadership interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a standard compensation practice for directors in the biotechnology sector, comparable to equity incentive plans at companies like Moderna, BioNTech, or Gilead Sciences, which often use similar mechanisms to retain talent and incentivize long-term growth.

Related Party Transactions

• The grant of stock options to Director Andrew Rappaport constitutes a related party transaction, which is a standard form of equity compensation for board members.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align management's long-term interests with shareholder value creation, potentially leading to improved company performance.
• Director (Andrew Rappaport): Receives a significant equity incentive, contingent on continued service and company performance.

Next Steps

• Andrew Rappaport's continued service to Olema Pharmaceuticals is required for the stock options to vest according to the specified schedule.

Key Dates

Keywords

Olema Pharmaceuticals, OLMA, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Andrew Rappaport